Condition
Dermatomyositis, Juvenile
Total Trials
5
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 4 (1)
Trial Status
Not Yet Recruiting2
Recruiting2
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT05879419Phase 4Active Not Recruiting
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
NCT07374107Recruiting
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
NCT07349667Not ApplicableNot Yet Recruiting
Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting
NCT06999109Not ApplicableNot Yet Recruiting
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
NCT06686524Phase 1RecruitingPrimary
Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
Showing all 5 trials